Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-08-23
2005-08-23
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S025000, C536S004100, C536S028100, C548S457000
Reexamination Certificate
active
06933315
ABSTRACT:
A compound called NATURA, which is a derivative of Isoindigo is useful in aiding the general health of a patient and specifically is beneficial in preventing or treating cancer. This compound and other related Isoindigo, Indigo and Indirubin derivatives are designed such that the bioactivity or bioavailability of the compound is increased. Methods of synthesizing these derivatives is also taught. In addition, pharmaceutical compositions that include a therapeutically effective amount of at least one of these derivatives and a pharmaceutically acceptable carrier. A method for the use of these pharmaceutical compositions and compounds is taught, wherein a therapeutically effective amount is administered to an animal having solid tumor cancer. The pharmaceutical composition or compound can be re-administered to the animal until a desired treatment or result is accomplished.
REFERENCES:
patent: 5696092 (1997-12-01), Patierno et al.
patent: WO 99/62503 (1999-12-01), None
patent: WO 00/61124 (2000-10-01), None
patent: WO 00/61555 (2000-10-01), None
Chunmin Li et al, Bull. Chem. Soc. Jpn., 1996, 69, 1621-1627.
Alessi, D. R., et al., “PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo,”J Biol Chem, vol. 270, No. 46, pp. 27489-27494 (1995).
Boehrer, S., et al., “In lymphatic cells par-4 sensitizes to apoptosis by down-regulating bcl-2 and promoting disruption of mitochondrial membrane potential and caspase activation,”Cancer Res, vol. 62, No. 6, pp. 1768-1775 (2002).
Buchdunger, E. et al., “Bcr-Abl inhibition as a modality of CML therapeutic,”Biochim Biophys Acta, vol. 1551, No. 1, pp. M11-18 (2001).
Buolamwini, J.K., “Cell Cycle Molecular Targets in Novel Anticancer Drug Discovery,”Curr. Pharm. Design, vol. 6, pp. 379-392 (2000).
Damiens, E. et al., “Anti-mitotic properties of indirubin-3′-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest,”Oncogene, vol. 20, No. 29, pp. 3786-3797 (2001).
DiPaola, R.S. et al., “Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer,”N Engl J Med, vol. 339, No., 12, pp. 785-791 (1998).
Druker, B.J. et al., “Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome,”N Engl J Med, vol. 344, No. 14, pp. 1038-1042 (2001).
Freitas, J.J. et al., “Walker-256 tumor growth causes oxidative stress in rat brain,”J Neurochem, vol. 77, No. 2, pp. 655-663 (2001).
Frey, R. S. et al., “Effects of genistein on cell proliferation and cell cycle arrest in nonneoplastic human mammary epithelial cells: involvement of Cdc2, p21](waf/cip1), p27(kip1), and Cdc25C expression,”Biochem Pharmacol, vol. 61, No. 8, pp. 979-989 (2001).
Furukawa, Y., “Cell cycle control genes and hematopoietic cell differentiation,”Leuk Lymphoma, vol. 43, No. 2, pp. 225-231 (2002).
Gianni, L. et al., “Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans,”J Clin Oncol, vol. 13, No. 1, pp. 180-190 (1995).
Gray, N. et al., “ATP-site Directed Inhibitors of Cyclin-dependent Kinases,”Curr. Medicinal Chem., vol. 6, No. 9, pp. 859-875 (1999).
Han, J., “Traditional Chinese medicine and the search for new antineoplastic drugs,”.J Ethnopharmacol, vol. 24, No. 1, pp. 1-17 (1988).
Hoessel, R. et al., “Indirubin, the active constituent of a Chinese Antileukaemia medicine, inhibits cyclin-dependent kinases,” Macmillan Magazines Ltd., Nature Cell Biology, vol. 1, pp. 60-67 (1999).
Huizing, M.T. et al., “Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients,”J Clin Oncol, vol. 11, No. 11, pp. 2127-2135 (1993).
Ji, X.J. et al., “Pharmacological studies of meisoindigo: absorption and mechanism of action,”Biomed Environ Sci, vol. 4, No. 3, pp. 332-337 (1991).
Kong, M., et al., “Cyclin F regulates the nuclear localization of cyclin B1 through a cyclin-cyclin interaction,”Embo J, vol. 19, No. 6, pp. 1378-1388 (2000).
Kreis, W. et al., “Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines,”Br J Urol, vol. 79, No. 2, pp. 196-202 (1997).
Kunikata, T. et al., “Indirubin inhibits inflammatory reactions in delayed-type hypersensitivity,”Eur J Pharmacol, vol. 410, No. 1, pp. 93-100 (2000).
Leclerc et al., “Indirubins Inhibit Glycogen Synthase Kinase-3β and DCK5/P25, Two Protein Kinases Involved in Abnormal Tau Phosphorylation in Alzheimer's Disease”,J. Biol. Chem., vol. 276, No. 1, pp. 251-260 (2001).
Li, C. et al., “The Synthesis, Antileukemic Activity, and Crystal Structures of Indirubin Derivatives,”Bull. Chem. Soc. Jpn., vol. 69, pp. 1621-1627 (1996).
Li, X.K. et al., “Huanglian, A chinese herbal extract, inhibits cell growth by suppressing the expression of cyclin B1 and inhibiting CDC2 kinase activity in human cancer cells,”Mol Pharmacol, vol. 58, No. 6, pp. 1287-1293 (2000).
Liu, X.M. et al., “Induction of differentiation and down-regulation of c-myb gene expression in ML-1 human myeloblastic leukemia cells by the clinically effective anti-leukemia agent meisoindigo,”Biochem Pharmacol, vol. 51, No. 11, pp. 1545-1551 (1996).
Marko, D. et al., “Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells,”Br J Cancer, vol. 84, No. 2, pp. 283-289 (2001).
Merck Manual of Diagnosis and Therapy, 15thEdition, pp. 1218-1219 (1987).
Mitani, N. et al., “Inhibitory effect of berberine on the mediastinal lymph node metastasis produced by orthotopic implantation of Lewis lung carcinoma,”Cancer Lett, vol. 165, No. 1, pp. 35-42 (2001).
Morgan, D.O., “Principles of CDK regulation,”Nature, vol. 374, No. 6518, pp. 131-134 (1995).
Ohtsu, T. et al., “Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion,”Clin Cancer Res, vol. 1, No. 6, pp. 599-606 (1995).
Senderowicz, A.M., “Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies,”Leukemia, vol. 15, No. 1, pp. 1-9 (2001).
Sharifi, N. et al., “Targeted chemotherapy: chronic myelogenous leukemia as a model,”J Mol Med, vol. 80, No. 4, pp. 219-232 (2002).
Steinman, R. A., “Cell cycle regulators and hematopoiesis,”Oncogene, vol. 21, No. 21, pp. 3403-3413 (2002).
Wang, L.G., et al., “Activation on casein kinase II in ML-1 human myeloblastic leukemia cells requires IGF-1 and transferrin,”J Leukoc Biol, vol. 57, No. 2, pp. 332-334 (1995).
Wang, L.G., et al., “Down-regulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter of the PSA gene in LNCaP cells,”Cancer Res, vol. 57, No. 4, pp. 714-719 (1997).
Wicki, A. et al., “The Rho/Rho-kinase and the phosphatidylinositol 3-kinase pathways are essential for spontaneous locomotion of Walker 256 carcinosarcoma cells,”Int J Cancer, vol. 91, No. 6, pp. 763-771 (2001).
Wu-Wong, J. R., et al., “Identification and characterization of A-105972, an antineoplastic agent,”Cancer Res, vol. 61, No. 4, pp. 1486-1492 (2001).
Yamaura, T., et al., “Model for mediastinal lymph node metastasis produced by orthotopic intrapulmonary implantation of lung cancer cells in mice,”Hum Cell, vol. 12, No. 4, pp. 197-204 (1999).
Chen Ruihuan
Liu Xiaomei
Wang Longgui
LandOfFree
Derivatives of isoindigo, indigo and indirubin and methods... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Derivatives of isoindigo, indigo and indirubin and methods..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Derivatives of isoindigo, indigo and indirubin and methods... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3502000